Chongqing Lummy Pharmaceutical Asset Resilience Ratio
Chongqing Lummy Pharmaceutical asset resilience ratio. Chongqing Lummy Pharmaceutical (300006) has an Asset Resilience Ratio of -0.19% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Chongqing Lummy Pharmaceutical defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chongqing Lummy Pharmaceutical (2007–2022)
Asset resilience ratio of Chongqing Lummy Pharmaceutical from 2007 to 2022. This chart shows how Chongqing Lummy Pharmaceutical's Asset Resilience Ratio has changed over time. Read Chongqing Lummy Pharmaceutical debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chongqing Lummy Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Chongqing Lummy Pharmaceutical asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-5.53 Million | -0.19% |
| Total Liquid Assets | CN¥-5.53 Million | -0.19% |
Asset Resilience Insights
- Limited Liquidity: Chongqing Lummy Pharmaceutical maintains only -0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Chongqing Lummy Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Chongqing Lummy Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
Novo Nordisk A/S
CO:NOVO-B |
Drug Manufacturers - General | 0.09% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR |
Drug Manufacturers - General | 0.07% |
Chongqing Lummy Pharmaceutical Asset Resilience Ratio by Year (2007–2022)
Chongqing Lummy Pharmaceutical asset resilience ratio by year from 2007 to 2022. The table below shows the annual Asset Resilience Ratio data for Chongqing Lummy Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.29% | CN¥-8.78 Million ≈ $-1.29 Million |
CN¥3.05 Billion ≈ $447.04 Million |
-0.09pp |
| 2021-12-31 | -0.20% | CN¥-5.87 Million ≈ $-858.97K |
CN¥2.93 Billion ≈ $428.28 Million |
+0.15pp |
| 2020-12-31 | -0.35% | CN¥-11.00 Million ≈ $-1.61 Million |
CN¥3.15 Billion ≈ $460.62 Million |
-0.01pp |
| 2019-12-31 | -0.34% | CN¥-11.81 Million ≈ $-1.73 Million |
CN¥3.50 Billion ≈ $512.37 Million |
+0.03pp |
| 2018-12-31 | -0.37% | CN¥-11.68 Million ≈ $-1.71 Million |
CN¥3.14 Billion ≈ $459.59 Million |
-0.42pp |
| 2013-12-31 | 0.05% | CN¥1.10 Million ≈ $160.96K |
CN¥2.18 Billion ≈ $319.31 Million |
-0.10pp |
| 2010-12-31 | 0.15% | CN¥1.33 Million ≈ $195.32K |
CN¥884.01 Million ≈ $129.36 Million |
-0.04pp |
| 2009-12-31 | 0.19% | CN¥1.27 Million ≈ $185.50K |
CN¥653.63 Million ≈ $95.65 Million |
-0.27pp |
| 2008-12-31 | 0.46% | CN¥1.23 Million ≈ $180.46K |
CN¥268.56 Million ≈ $39.30 Million |
-0.19pp |
| 2007-12-31 | 0.65% | CN¥1.40 Million ≈ $204.86K |
CN¥214.69 Million ≈ $31.42 Million |
-- |
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more